Visceral Heterotaxy 9 (HTX9): A Comprehensive Disease Characterization Report

Disease: Visceral Heterotaxy 9 (HTX9) OMIM: #618948 · MONDO: MONDO:0030070 · Category: Mendelian (autosomal recessive) Causal gene: MNS1 (Meiosis-specific nuclear structural protein 1; HGNC:29636; 15q21.3)

Summary

Visceral heterotaxy 9 (HTX9) is a rare autosomal-recessive disorder of left–right (L–R) body-axis determination caused by biallelic loss-of-function (LOF) variants in MNS1. MNS1 is a 495–amino-acid coiled-coil microtubule inner protein (MIP) that decorates the doublet microtubules of motile cilia and sperm flagella and supports docking of the outer dynein arms (ODAs) through interaction with the ODA docking-complex (ODA-DC) component CCDC114/ODAD1. When both MNS1 alleles are inactivated, the motile monocilia of the embryonic node cannot generate the directional leftward fluid flow that normally breaks embryonic symmetry. The consequence is randomization of situs — affected individuals may present with situs solitus (normal), situs inversus totalis, or situs ambiguus/heterotaxy — accompanied by male infertility (immotile, structurally abnormal sperm) and, variably, sinopulmonary disease reminiscent of primary ciliary dyskinesia (PCD).

The disease is defined by a small human evidence base: two independent studies describing fewer than ~10 affected individuals from consanguineous and founder (Old Order Amish) families (PMID: 30148830; PMID: 31534215), supported by a foundational Mns1-knockout mouse that recapitulates situs inversus, hydrocephalus, male sterility, and axonemal ODA/"9+2" defects (PMID: 22396656). Population-database analysis (gnomAD v4) confirms that MNS1 is tolerant of heterozygous LOF (consistent with a recessive mechanism in which carriers are unaffected) and that the reported pathogenic alleles are rare, with a recurrent p.Arg242* nonsense allele and a near-private Amish founder frameshift.

HTX9 sits within the motile-ciliopathy / heterotaxy spectrum. Its clinical burden is driven not by the laterality label itself but by the associated congenital heart disease (when present in heterotaxy) and by fertility consequences. There is no disease-specific pharmacologic or gene therapy; management is supportive and organ-directed (cardiac surgical palliation, treatment of respiratory infection, assisted reproduction for male infertility, genetic counseling). This report synthesizes six confirmed findings across 31 reviewed papers and details each of the 15 requested characterization domains, flagging where evidence is absent.

Key Findings

Finding 1 — HTX9 is caused by biallelic loss-of-function variants in MNS1

Two independent human genetic studies converge on recessive MNS1 LOF as the cause of HTX9. Ta-Shma et al. (2018) identified two recessive LOF MNS1 mutations across four consanguineous families: a homozygous nonsense mutation p.Arg242* in four males with laterality defects and infertility, and a homozygous nonsense mutation p.Gln203* in one female with laterality defects and recurrent respiratory infections. As the authors state, "we identified two recessive loss-of-function MNS1 mutations in five individuals from four consanguineous families: 1) a homozygous nonsense mutation p.Arg242* in four males with laterality defects and infertility and 2) a homozygous nonsense mutation p.Gln203* in one female with laterality defects and recurrent respiratory infections additionally carrying homozygous mutations in DNAH5" (PMID: 30148830).

Leslie et al. (2020) independently confirmed the locus in an Old Order Amish family, mapping a single 2.34 Mb region of autozygosity to 15q21.3 and identifying a homozygous frameshift variant: "This identified a single shared (2.34 Mb) region of autozygosity on chromosome 15q21.3 as the likely disease locus, in which we identified a single candidate biallelic frameshift variant in MNS1 [NM_018365.2: c.407_410del; p.(Glu136Glyfs*16)]" (PMID: 31534215). MNS1 encodes Meiosis-specific nuclear structural protein 1 (HGNC:29636, chromosome 15q21.3).

Finding 2 — MNS1 is an axonemal protein that docks outer dynein arms via CCDC114; its loss causes ODA defects

MNS1 localizes to motile-cilia and flagellar axonemes and physically engages the ODA docking machinery. Ta-Shma et al. showed that "Immunofluorescence analysis further revealed that MNS1 localizes to the axonemes of respiratory cilia as well as sperm flagella in human" and that "co-immunoprecipitation and yeast two hybrid analyses demonstrated that MNS1 dimerizes and interacts with the ODA docking complex component CCDC114" (PMID: 30148830). Ultrastructural analysis of patient cilia showed a subtle ODA defect resembling that of Mns1-deficient mice. This positions MNS1 within the same functional module as established ODA-DC PCD genes (CCDC114/ODAD1, CCDC151, ARMC4, TTC25) — a module whose disruption is a common cause of PCD with laterality randomization (PMID: 25192045, PMID: 27486780).

Finding 3 — Laterality is randomized, penetrance is incomplete, and the phenotype is milder than classic heterotaxy

A hallmark of HTX9 is randomized rather than uniformly inverted situs. In the Amish pedigree, "Genotyping of multiple family members identified randomisation of the laterality defects in other homozygous individuals, with all wild type or MNS1 c.407_410del heterozygous carriers being unaffected, consistent with an autosomal recessive mode of inheritance" (PMID: 31534215). Thus homozygotes may show situs inversus totalis, situs ambiguus/heterotaxy, or even situs solitus, while heterozygous carriers are clinically normal. The affected phenotype centers on situs abnormality plus male infertility, with variable respiratory infection. The total reported human cohort remains fewer than ~10 individuals, all from consanguineous or founder backgrounds — a key caveat when generalizing severity.

Finding 4 — The Mns1-knockout mouse recapitulates HTX9 and extends the phenotype

Zhou et al. (2012) generated the foundational mouse model, demonstrating that MNS1 is an integral axonemal component: "MNS1 is expressed in the germ cells in the testes and localizes to sperm flagella in a detergent-resistant manner, indicating that it is an integral component of flagella" (PMID: 22396656). MNS1-deficient males are sterile with markedly reduced sperm production and immotile, short-tailed sperm. The model recapitulates the human laterality defect and reveals additional features: "In MNS1-deficient sperm flagella, the characteristic arrangement of '9+2' microtubules and outer dense fibers are completely disrupted. In addition, MNS1-deficient mice display situs inversus and hydrocephalus. MNS1-deficient tracheal motile cilia lack some outer dynein arms in the axoneme" (PMID: 22396656). Hydrocephalus (from ependymal motile-cilia dysfunction) is demonstrated in mouse but not yet firmly established as a human HTX9 feature. Mouse Mns1 = NCBI Gene 17427.

Finding 5 — gnomAD confirms recessive constraint and rarity of pathogenic alleles

gnomAD v4 constraint metrics for MNS1 (ENSG00000138587; chr15:56,421,544–56,465,137) show the gene is not depleted of heterozygous LOF: pLI ≈ 0 (3.6e-19), observed/expected LoF (oe_lof) = 0.875 (90% CI 0.714–1.079; LOEUF ≈ 1.08), lof_z = 0.90. This is exactly the signature expected for a recessive disease gene where a single functional allele suffices for health. The reported pathogenic alleles are rare in gnomAD v4 exomes: p.Arg242Ter (c.724C>T) AC=253/AN=1,453,772 (AF ≈ 1.74×10⁻⁴; a recurrent nonsense allele); p.Gln203Ter (c.607C>T) AC=7 (AF ≈ 4.8×10⁻⁶); and the Amish founder p.Glu136GlyfsTer16 (c.407_410del) AC=2/AN=1,458,458 (AF ≈ 1.37×10⁻⁶, near-private). All appear only as rare heterozygotes.

Finding 6 — MNS1 is a 495-aa coiled-coil microtubule inner protein with a TPH domain

UniProt Q8NEH6 (human MNS1, 495 aa) describes a large coiled-coil region (residues ~28–410) and a Trichohyalin-Plectin-Homology (TPH) domain (~114–465; Pfam PF13868 "TPH"; InterPro IPR043597; MNS1 family InterPro IPR026504; PANTHER PTHR19265). Functionally, MNS1 is annotated as a microtubule inner protein (MIP) of the dynein-decorated doublet microtubules (DMTs) of the ciliary/flagellar axoneme, required for motile-cilia beating and sperm-flagella assembly. Subcellular localization: nucleus, cilium axoneme, flagellum axoneme. It forms oligomers and interacts with ODAD1 (=CCDC114), BBOF1, and CFAP65; tissue specificity is nasal respiratory epithelium and sperm. The self-oligomerization and CCDC114 interaction are experimentally supported: "co-immunoprecipitation and yeast two hybrid analyses demonstrated that MNS1 dimerizes and interacts with the ODA docking complex component CCDC114" (PMID: 30148830).

Detailed Disease Characterization (Sections 1–15)

1. Disease Information

HTX9 is a Mendelian disorder of visceral laterality (left–right asymmetry) within the motile-ciliopathy spectrum. Affected individuals fail to establish normal L–R patterning during early embryogenesis, producing situs abnormalities and, in males, infertility.

Synonyms / related terms: heterotaxy visceral 9, autosomal recessive; MNS1-related laterality defect; situs inversus with male infertility (MNS1). The disease-level information is aggregated from case reports/family studies and a mouse model — not from EHR/individual-patient registries.

2. Etiology

• Primary cause (genetic): biallelic (homozygous or compound-heterozygous) loss-of-function variants in MNS1 (Findings 1, 5). Mechanism is loss of function via nonsense/frameshift alleles producing truncated, non-functional protein.
• Genetic risk factors: the causal locus is MNS1; carrier (heterozygous) state confers no disease risk. Consanguinity and founder-population membership (Old Order Amish) are the dominant risk contexts because they raise homozygosity for rare recessive alleles.
• Environmental risk factors: none established. No toxin, infection, or lifestyle factor is implicated in HTX9 causation.
• Protective factors: a single functional MNS1 allele is fully protective (recessive; gnomAD LOF tolerance, Finding 5). No specific protective modifier alleles are described.
• Gene–environment interactions: none documented. In one patient, co-occurring homozygous DNAH5 mutations were noted (PMID: 30148830), illustrating potential oligogenic contribution within the shared ciliary pathway rather than a G×E effect.

3. Phenotypes

Characteristics: onset is congenital for laterality/cardiac features and reproductive-age for infertility. Severity is variable and strongly dependent on the presence and type of congenital heart disease. Progression of the laterality trait itself is stable (a fixed structural condition), though associated CHD and infections drive morbidity over time. Quality-of-life impact is dominated by cardiac disease (surgical burden) and infertility; individuals with situs inversus totalis and no CHD may be minimally affected.

4. Genetic / Molecular Information

• Causal gene: MNS1 (HGNC:29636; OMIM *610766; 15q21.3; NCBI Gene 55329; Ensembl ENSG00000138587; UniProt Q8NEH6).
• Pathogenic variants (all germline, LOF):

• ACMG classification: all three are LOF (nonsense/frameshift) variants meeting pathogenic criteria (PVS1 + segregation + rarity).
• Functional consequence: loss of function (premature termination / truncated protein lacking the C-terminal region needed for axonemal assembly and ODA-DC interaction).
• Modifier genes: possible oligogenic contribution from co-inherited ciliary-gene variants (e.g., DNAH5 in one case, PMID: 30148830). No formal modifier-gene mapping exists.
• Epigenetic information: none reported for HTX9.
• Chromosomal abnormalities: none — HTX9 is a single-gene disorder, not a copy-number/aneuploidy syndrome. (Note: unrelated heterotaxy cases involve CNVs at other loci, PMID: 29843777.)

5. Environmental Information

No environmental, lifestyle, or infectious agents are implicated in causing HTX9. This is a purely genetic Mendelian disorder. (Recurrent respiratory infections in some patients are a consequence of impaired mucociliary clearance, not a cause.)

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic LOF variant in MNS1 (nonsense/frameshift) → leads to loss of full-length MNS1 protein (loss of function). (demonstrated — Findings 1, 5)
2. Loss of MNS1 → results in failure to properly assemble/stabilize the doublet-microtubule inner scaffold and to dock outer dynein arms via CCDC114/ODAD1. (demonstrated by co-IP/Y2H and TEM — Findings 2, 6)
3. Defective ODA docking → leads to reduced/absent axonemal outer dynein arms and impaired motor force generation. (demonstrated in human cilia and mouse trachea — Findings 2, 4) 4a. In embryonic nodal monocilia: impaired beating → fails to generate directional leftward nodal flow → fails to break L–R symmetry → results in randomized situs (solitus / inversus / ambiguus). (inferred from ODA-DC ciliopathy paradigm + mouse situs inversus — Findings 3, 4) 5a. Randomized cardiac/visceral situs → can result in congenital heart disease and malposition of thoraco-abdominal organs. (clinical) 4b. In sperm flagella: loss of MNS1 → disrupts the "9+2" axoneme and outer dense fibers → results in immotile, structurally abnormal sperm → male infertility. (demonstrated in mouse — Finding 4) 4c. In ependymal/respiratory motile cilia: ODA loss → impaired mucociliary clearance → recurrent respiratory infection (human, variable) and → hydrocephalus (mouse-demonstrated, human-inferred). (Finding 4)

Upstream events: the MNS1 mutation and protein loss. Downstream: organ-level malformations and functional deficits. The branch point is the cell type in which the defective motile cilium/flagellum operates (node vs. sperm vs. ependyma/airway).

• Molecular pathways / complexes: axonemal dynein assembly and docking (ODA-DC module: MNS1–CCDC114/ODAD1–CCDC151–ARMC4–TTC25). GO biological processes: GO:0003341 (cilium movement), GO:0060287 (epithelial cilium movement involved in determination of L–R asymmetry), GO:0007368 (determination of L–R symmetry), GO:0036158 (outer dynein arm assembly), GO:0030317 (flagellated sperm motility).
• Cellular processes: motile ciliary beating, ciliogenesis, spermiogenesis, mucociliary clearance.
• Protein dysfunction: loss of function of a coiled-coil MIP (Q8NEH6); truncation abolishes axonemal incorporation.
• Cell types (CL): ciliated node cell / embryonic monociliated node cell; CL:0000064 (ciliated cell); CL:0002145 (ciliated columnar cell of tracheobronchial tree); CL:0000019 (sperm); ependymal cell CL:0000065.
• Immune / metabolic / autoimmune involvement: none intrinsic; respiratory infections are secondary to impaired clearance.

7. Anatomical Structures Affected

• Primary organs / systems: cardiovascular system (heart UBERON:0000948, great vessels), abdominal viscera (spleen UBERON:0002106, liver UBERON:0002107, stomach UBERON:0000945, intestine), lungs/airway (UBERON:0002048), male reproductive tract (testis UBERON:0000473; sperm flagellum). The embryonic left–right organizer / node (UBERON:0004341) is the initiating site.
• Secondary involvement: brain ventricular system (hydrocephalus — mouse); recurrent airway infection.
• Tissue/cell level: motile ciliated epithelium (respiratory, ependymal), nodal monociliated cells, spermatozoa.
• Subcellular (GO cellular component): ciliary axoneme GO:0005930, motile cilium GO:0031514, sperm flagellum GO:0036126, axonemal microtubule GO:0005879, outer dynein arm GO:0036157, nucleus GO:0005634.
• Lateralization: by definition an abnormality of left–right asymmetry; situs may be fully mirror-imaged (situs inversus totalis) or discordant/asymmetric across organs (situs ambiguus/heterotaxy).

8. Temporal Development

• Onset: laterality and cardiac features are congenital (determined in early embryogenesis at the L–R organizer). Infertility manifests at reproductive age. Respiratory symptoms, when present, typically begin in childhood.
• Progression: the laterality trait is structurally fixed and stable. Clinical course is dominated by associated CHD (may require staged surgical palliation) and by recurrent infections; both can be progressive if untreated. Disease is lifelong.
• Critical period: the narrow embryonic window of nodal flow / symmetry breaking (gastrulation/early somitogenesis) is when the primary lesion acts — there is no postnatal opportunity to alter situs.
• Remission: not applicable to the structural defect.

9. Inheritance and Population

• Inheritance: autosomal recessive (biallelic LOF; unaffected heterozygous carriers — Findings 1, 3, 5).
• Penetrance / expressivity: the situs phenotype shows incomplete/randomized penetrance — homozygotes may be situs solitus, inversus, or ambiguus (Finding 3). Male infertility appears more consistently penetrant. Expressivity is variable.
• Founder effect: yes — the p.Glu136Glyfs*16 allele is an Old Order Amish founder variant (PMID: 31534215). Consanguinity underlies the other reported families (PMID: 30148830).
• Carrier frequency: rare in general populations; p.Arg242* is the most common pathogenic allele (gnomAD AF ≈1.74×10⁻⁴), others near-private (Finding 5).
• Epidemiology: true prevalence/incidence of HTX9 specifically is unknown (fewer than ~10 published individuals). For context, all-cause heterotaxy affects roughly 1 in 10,000 births and is enriched in congenital heart disease cohorts; PCD (the broader motile-ciliopathy class) is estimated at ~1 in 10,000–20,000.
• Sex ratio: both sexes affected for laterality; the infertility phenotype is male-specific by nature. Reported cases skew male because infertility prompted ascertainment.
• No genetic anticipation (not a repeat-expansion disorder). Germline mosaicism not reported.

10. Diagnostics

• Clinical/imaging: situs is established by echocardiography, chest radiography, abdominal ultrasound, CT/MRI documenting cardiac position, atrial appendage morphology, spleen status (asplenia/polysplenia), and vessel anatomy. Prenatal ultrasound can detect heterotaxy features (PMID: 37485264, PMID: 35518361).
• Semen analysis: asthenozoospermia / immotile sperm in affected males.
• Ciliary studies: nasal nitric oxide (nNO), high-speed video microscopy, and transmission electron microscopy (TEM) may show ODA/ODA-DC abnormalities; immunofluorescence for ODA-DC components. These PCD workups are relevant where a PCD-like presentation exists (PMID: 24577564).
• Genetic testing (definitive): whole-exome or whole-genome sequencing, or PCD/heterotaxy/laterality gene panels that include MNS1; single-gene testing where a founder allele is suspected (e.g., Amish p.Glu136Glyfs*16). Homozygosity mapping is powerful in consanguineous/founder families (used in both index studies). WES is high-yield in genetically heterogeneous PCD (PMID: 41948467).
• Differential diagnosis: other heterotaxy/PCD genes — DNAH5, DNAH11, CCDC114/ODAD1, CCDC151, ARMC4, TTC25, ZIC3, NODAL, LEFTY, CFC1, SHROOM3, WDR16 — distinguished by gene identified and by presence/absence of classic PCD airway disease (PMID: 31040315, PMID: 27486780, PMID: 25192045, PMID: 21936905, PMID: 25469542).

11. Outcome / Prognosis

• Prognosis is determined by associated congenital heart disease. Isolated situs inversus totalis without structural heart disease carries near-normal life expectancy. Heterotaxy with complex CHD (single-ventricle physiology, anomalous pulmonary venous connection, atrioventricular septal defect) carries substantial morbidity and mortality despite surgery. Large heterotaxy cohorts report overall mortality around 40% with limited improvement over decades, and worst outcomes for univentricular circulation with totally anomalous pulmonary venous connection (PMID: 32647064).
• Male infertility: effectively complete for natural conception; assisted reproduction (ICSI) may be considered.
• Respiratory morbidity: where a PCD-like phenotype exists, chronic sinopulmonary infection and bronchiectasis risk apply.
• Complications: arrhythmia and heterotaxy-associated surgical risk (PMID: 41404994), intestinal malrotation/volvulus risk (Ladd-procedure considerations, PMID: 36941169), asplenia-related infection risk.
• Prognostic factors: ventricular morphology, pulmonary venous anatomy, spleen status, era of care.

12. Treatment

There is no disease-specific or curative therapy for HTX9; management is supportive and organ-directed.

• Pharmacotherapy / pharmacogenomics: none specific to HTX9.
• Gene, cell, RNA, targeted, or immunotherapy: none approved or in trials for HTX9. PCD gene therapy is an emerging general research direction, not HTX9-specific (PMID: 42135132).
• Personalized medicine: genotype confirmation guides counseling and reproductive planning rather than drug selection.

13. Prevention

• Primary prevention: not possible for the genetic lesion; genetic counseling and carrier/cascade testing in affected families (especially founder Amish and consanguineous kindreds) inform reproductive decisions. Preimplantation genetic testing and prenatal diagnosis are options for known familial variants.
• Secondary prevention: prenatal ultrasound/fetal echocardiography for early detection of heterotaxy/CHD; postnatal imaging screening.
• Tertiary prevention: management of asplenia (vaccination, antibiotic prophylaxis), surveillance and timely surgery for CHD, aggressive treatment of respiratory infection to prevent bronchiectasis, consideration of prophylactic Ladd procedure where indicated.
• Immunization / public health / environmental measures: not applicable to disease causation.

14. Other Species / Natural Disease

• Taxonomy / orthologs: Mns1 is conserved in mouse (NCBI Gene 17427, Mus musculus, NCBI:txid10090) and other vertebrates. The mouse ortholog provides the principal experimental model (Finding 4).
• Natural disease in other species: no naturally occurring companion-animal or wildlife MNS1 disease is catalogued in OMIA at review time; the mouse phenotype is engineered, not spontaneous.
• Comparative biology: the L–R symmetry-breaking role of motile nodal cilia and the ODA-DC machinery is deeply conserved across vertebrates (mouse, zebrafish), which is why ODA-DC gene defects (e.g., CCDC151, TTC25) produce situs defects across species (PMID: 25192045, PMID: 27486780).
• Zoonotic potential: none (genetic disease).

15. Model Organisms

• Principal model — mouse (Mus musculus): the Mns1-knockout recapitulates HTX9's core features — situs inversus, hydrocephalus, male sterility with disrupted "9+2" axoneme and outer dense fibers, and tracheal ODA loss (PMID: 22396656). This is a high-fidelity model for the ciliary/flagellar mechanism and laterality randomization.
• Model type: mammalian genetic knockout (constitutive LOF).
• Phenotype recapitulation: strong for laterality, sperm ultrastructure/infertility, and ODA defects; the model additionally reveals hydrocephalus, well-established in mouse but not yet confirmed as a human HTX9 feature.
• Limitations: mouse cannot fully model the variable human sinopulmonary/CHD spectrum; incomplete penetrance/randomization means large cohorts are needed to quantify situs outcomes.
• Complementary systems: zebrafish and Xenopus are established platforms for heterotaxy-candidate-gene testing generally (PMID: 26910255); ODA-DC pathway partners have been modeled in zebrafish/mouse (PMID: 25192045, PMID: 27486780). Resources: MGI, IMPC/KOMP, IMSR.

Mechanistic Model / Interpretation

   MNS1 biallelic LOF variant (p.Arg242*, p.Gln203*, p.Glu136Glyfs*16)
     │  (loss of function; demonstrated)
     ▼
       Loss of full-length MNS1 (coiled-coil / TPH-domain MIP)
     │  (microtubule inner protein of axonemal doublets)
     ▼
   Failed doublet-MT stabilization + failed ODA docking via CCDC114/ODAD1
     │  (co-IP/Y2H + TEM; demonstrated)
     ▼
Reduced / absent axonemal outer dynein arms → weak motor force
     │
┌────────────┼───────────────────────────┐
▼            ▼                             ▼
  NODAL MONOCILIA   SPERM FLAGELLUM          RESPIRATORY / EPENDYMAL CILIA
  no leftward       disrupted "9+2" +        impaired mucociliary clearance
  nodal flow        outer dense fibers        │
│            │                        ├── recurrent airway infection (human, variable)
▼            ▼                        └── hydrocephalus (mouse; inferred human)
  RANDOMIZED       IMMOTILE SPERM →
  SITUS            MALE INFERTILITY
  (solitus /
   inversus /
   ambiguus)
│
▼
  CONGENITAL HEART DISEASE / organ malposition (when heterotaxy)

The unifying interpretation is that HTX9 is a cell-type-branched motile ciliopathy: a single molecular lesion (loss of an axonemal microtubule inner protein) produces divergent organ phenotypes depending on which motile cilium/flagellum fails. The randomization of situs — rather than uniform inversion — is the diagnostic signature and reflects loss of the deterministic leftward nodal flow, leaving L–R identity to chance. MNS1 belongs functionally alongside the ODA-DC PCD genes, which explains both the ODA ultrastructural defect and the PCD-like respiratory features seen in a subset of patients.

Evidence Base

All mechanistic and genetic claims specific to HTX9 rest on the three primary sources (two human, one mouse) plus curated population/protein databases. Broader heterotaxy/PCD papers are used only for contextual framing (differential diagnosis, pathway, prognosis), not to attribute HTX9-specific facts.

Limitations and Knowledge Gaps

1. Very small human cohort (<10 individuals) from consanguineous/founder families limits confidence in penetrance estimates, full phenotypic spectrum, and generalizability. Female fertility outcomes are essentially unstudied.
2. Hydrocephalus is robustly demonstrated in mouse but not confirmed as a human HTX9 feature — an important gap flagged throughout.
3. No prevalence/incidence data exist for HTX9 specifically; epidemiology is inferred from the broader heterotaxy/PCD literature.
4. Oligogenic contributions (e.g., co-inherited DNAH5) are noted anecdotally but not systematically studied; modifier genetics is unknown.
5. No experimental structure of MNS1 within a human HTX9-patient axoneme was retrieved; domain/function annotation is from UniProt/Pfam/InterPro and homology.
6. No therapeutics, biomarkers, or clinical trials target HTX9 directly; treatment evidence is extrapolated from heterotaxy/CHD and PCD management.
7. ICD/MeSH mapping is approximate — no HTX9-specific billing code exists.

Proposed Follow-up Experiments / Actions

1. Assemble an international MNS1 patient registry (GeneMatcher/Matchmaker Exchange) to expand N, quantify penetrance of situs subtypes, and define the true phenotypic range (including whether human hydrocephalus, sinopulmonary disease, and female subfertility occur).
2. Cryo-EM of patient-derived or reconstituted axonemal doublets with/without MNS1 to map exactly how MNS1 stabilizes the DMT lattice and positions the ODA-DC — testing the mechanistic step that is currently inferred.
3. Standardized TEM/immunofluorescence panels on HTX9 nasal-brush and sperm samples to define the ODA/ODA-DC defect signature for diagnostic use.
4. Genotype–situs correlation study across ODA-DC genes (MNS1, CCDC114, CCDC151, ARMC4, TTC25) to test whether MNS1 loss yields a milder/more randomized situs distribution than other module members.
5. Founder-allele carrier screening in the Old Order Amish (p.Glu136Glyfs*16) to establish carrier frequency and enable cascade counseling.
6. Reproductive-outcome study of ICSI success in MNS1-related male infertility.
7. Conditional/tissue-specific mouse models (node vs. germ cell vs. ependyma) to dissect branch points and test whether the hydrocephalus phenotype has a human correlate.

Report compiled from 6 confirmed findings across 31 reviewed papers and curated database analyses (gnomAD v4, UniProt/Pfam/InterPro). Evidence sources are labeled as human clinical, model organism, in vitro, or computational throughout.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0030070 (2 mentions) - the report calls it "MONDO"; MONDO calls it heterotaxy, visceral, 9, autosomal, with male infertility
• HP:0011885 (1 mention) - the report calls it "Abnormal visceral situs"; HP calls it Hemorrhage of the eye
• UBERON:0004341 (1 mention) - the report calls it "left–right organizer / node"; UBERON calls it primitive streak

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0030680 (1 mention) - the report calls it "Abnormal cardiovascular morphology"; HP calls it Abnormal cardiovascular system morphology
• HP:0012207 (1 mention) - the report calls it "Abnormal sperm motility"; HP calls it Reduced sperm motility